19 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 NEWS biotech and pharmaceutical companies. Nikki Whitfield, Chief Executive Officer, said, “We are delighted to complete the build of our sterile facility. The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services.” The sterile facility will feature two cleanrooms with advanced VHP isolation technology and carry out GMP manufacturing of sterile drug products making use of existing fullservice formulation development and quality control laboratories. Jon Austwick, Director of Quality & Compliance, said: “This expansion illustrates our continued investment in our capabilities to support drug developers to scale and accelerate the path to delivering safe and effective medicines to patients. The facility has been built with the highest level of quality and is a testament to our internal teams and build vendor who have worked tirelessly over the past 12 months to bring our vision to life”. This investment in sterile drug product manufacturing enhances the existing service offering from Upperton, which provides formulation development across a broad range of dosage forms, clinical trial supply, and late-stage manufacturing for non-sterile dosage forms for both small molecules and biologics. Whilst the commissioning of the facility, along with the installation and validation of new equipment continues, Upperton will utilise existing expertise within their research & development and analytical teams to support the pre-formulation and stability studies for early proof-of concept products for parenteral, nasal and pulmonary delivery. Icrom announced the grand opening of its brand new Research & Development laboratory, specifically designed for the advancement of Highly Potent Active Pharmaceutical Ingredients (HPAPIs). This stateof-the-art facility represents a significant enhancement of Icrom’s existing capabilities and underscores the company’s commitment to innovation in the pharmaceutical sector. Spanning an impressive 100 square meters, the new lab is equipped with advanced isolators that can handle compounds classified up to OEB 6, ensuring the highest safety standards and operational efficiency. Additionally, dedicated isolators for analytical activities have been included to bolster R&D efforts, facilitating comprehensive support for the development and optimization of complex synthesis processes. The laboratory is already operational, with ongoing plans to integrate additional analytical techniques that will further enhance Icrom’s ability to innovate and deliver top-quality pharmaceutical products. This milestone reflects Icrom’s unwavering dedication to advancing healthcare solutions, as the company continues to push the boundaries of what is possible in the field of highly potent compounds. Icrom unveils cutting-edge R&D laboratory for highly potent active pharmaceutical ingredients
RkJQdWJsaXNoZXIy MjY2OTA4MA==